-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 4, Hengrui Medicine announced the effectiveness and safety of its new class 1 drug SHR8008 capsule in the treatment of acute vulvovaginal candida disease.
Hengrui will submit an application for communication and exchange of new drugs to the Drug Evaluation Center of the State Drug Administration in the near future
SHR8008 is a new type of oral azole antifungal drug, which can highly specifically inhibit the fungal CYP51 enzyme.
The SHR8008-302 study that reached the endpoint is a randomized, double-blind, double-simulated, fluconazole parallel-controlled, multi-center phase III clinical study evaluating the effectiveness and safety of SHR8008 capsules in the treatment of acute vulvovaginal candidiasis
Up to now, the accumulated research and development expenses of SHR8008 related projects are about 89.